NEWS | Innovation for Life
Prestige Biopharma announces International Non-proprietary Name for PBP1510
SINGAPORE, May 31, 2022 – Prestige Biopharma Limited, a Singapore-based biopharmaceutical company with operations in USA and South Korea, announced that its first-in-class antibody PBP1510 has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’ and was placed on the INN Recommended List by the World Health Organization (WHO).
“With its INN- Ulenistamab, PBP1510 is one step closer to commercialization. Not to mention pancreatic cancer has the highest mortality rate of all major cancers, we will try our utmost with PBP1510 so that it could provide significant benefit in all patients affected by PAUF-positive pancreatic cancer,” said Lisa S. Park, CEO of Prestige Biopharma.
INN-Ulenistamab, which is also known as a generic name, facilitates the identification of pharmaceutical substances or active pharmaceutical ingredients. Each INN is a unique name that is globally recognized and is public property. The name is given through a thorough examination and discussion on the drug by the WHO and INN experts.
PBP1510 (INN-Ulenistamab) is an anti-PAUF monoclonal antibody for pancreatic cancer treatment. It effectively counteracts the effects induced by PAUF (Pancreatic Adenocarcinoma Up-regulated Factor) which is known to play an important role in tumor growth and to be involved in the rapid progression of pancreatic cancer.
In 2020, PBP1510 (INN-Ulenistamab) has been granted Orphan Drug Designation (ODD) by the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and Korean MFDS. Currently, it is on Phase 1/2a clinical trial in France and Spain.
Meanwhile, Prestige Biopharma has recently published a research paper on Frontiers in Pharmacology revealing that PBP1510 may potentially treat ovarian cancer as well. The study showed that PAUF independently promotes tumor growth and metastasis in ovarian cancer cells, in a baseline PAUF dependent and saturable manner, thus an anti-PAUF antibody may sensitize and synchronize the anti-tumor effects of cytotoxic agents and prolong survival time for patients with ovarian cancer.